Windtree Secures $520 Million to Expand BNB Treasury Strategy

Windtree Therapeutics has announced up to $520 million in new funding, with 99% of proceeds earmarked for BNB acquisitions, signaling one of the most aggressive crypto treasury moves by a public biotech company.

Biotech Firm Windtree Doubles Down on Crypto With New BNB Plan

Windtree Therapeutics (NasdaqCM: WINT) is pivoting aggressively into digital assets, unveiling a $520 million funding package dedicated almost entirely to BNB crypto acquisitions. The strategy includes a $500 million equity line of credit (ELOC) and a $20 million stock purchase agreement with Build and Build Corp, with 99% of the proceeds allocated to BNB purchases.

According to the announcement, the ELOC underscores Windtree’s ambition to diversify its balance sheet with blockchain-based assets while maintaining its traditional biotech operations. This funding round is part of a broader plan to position Windtree as a hybrid innovator in both healthcare and digital finance.

“We are excited to incorporate these new facilities to enable our future BNB acquisitions as part of our BNB treasury strategy. The opportunity to secure additional funds for purchasing more BNB cryptocurrency is essential to our strategy,” stated Jed Latkin, CEO of Windtree.

Combined with previously announced initiatives, the company expects its BNB commitment to reach as high as $700 million, marking one of the largest corporate treasury strategies focused on a single altcoin.

Windtree stated that these moves aim to strengthen shareholder value, leveraging both the growth potential of BNB and the liquidity of blockchain ecosystems.